Clinical and basic studies on NM441 in ophthalmology

• Published in: Japanese Journal of Chemotherapy Vol. 44; no. Supplement1; pp. 551 - 553
• Main Authors: Hara, Jiro, Otani, Etsuko, Yasuda, Fuyuko, Kawaguchi, Satoshi, Kawamura, Toshihiko
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1996; 公益社団法人 日本化学療法学会
• Subjects: NM394; NM441; ニューキノロン系合成抗菌剤; 房水中濃度
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.44.Supplement1_551

We clinically evaluated NM441, a new pyridone carboxylic acid derivative, in anterior eye infections and studied the penetration of the drug into aqueous humor of cataractal patients at 1-4.7h after oral administration. In this trial, clinical cases were: hordeolum in 1, dacryocystitis in 1, and keratitis in 6 patients, whose ages ranged from 59 to 80 years (mean 69 years). NM441 was given at a dose of 200mg twice daily, and the duration of treatment was 3-8 days (mean 6 days). Clinical effect was excellent in 5, good in 3 cases, and no cases were assessed as poor. No adverse effect was observed. After a single oral dose of 200mg of NM441, the aqueous level of NM394 was 0.007-0.099μg/ml, and the aqueous/serum ratio was 1.8-12.4%. From the above results, we consider NM441 to be a useful antimicrobial agent for anterior eye infections.